Robert S. Warren, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Robert S. Warren, MD

Professor, Department of Surgery; Chief of Surgical Oncology, UCSF

Phone: (415) 353-9888 (appts)
Box 1932, UCSF
San Francisco, CA 94143-1932

View on UCSF Profiles

Cancer Center Membership

Associate Member ยป Cancer Genetics

Education

Cornell University, Ithaca, NY, 1966-1967, English
Lawrence University, Appleton, Wisconsin, 1967-1968, Biology
Univ. of Minnesota, Minneapolis, MN, B.A., 1969-1971, Physiology
Grad. School, Univ. of Minnesota, Minneapolis, MN, 1971-1975, Cell Biology
Med. School, Univ. of Minnesota, Minneapolis, MN, M.D., 1976-1980, Medicine


Professional Experience

  •     1980-1983, 1986-1988
        Surgery Internship and Residency, University of Minnesota
  •     1983-1986
        Fellowship, Memorial Sloan-Kettering Cancer Center; NY, NY
  •     1984-1985
        Associate Physician, Rockefeller University; NY, NY
  •     1988-1994
        Assistant Professor, Department of Surgery, UCSF
  •     1994-present
        Associate Professor, Department of Surgery, UCSF
  •     2000-present
        Chief, Surgical Oncology, UCSF
  •     2000-present
        Professor, Department of Surgery, UCSF

Honors & Awards

  • 1971
    BA magna cum laude
  • 1980
    Alpha Omega Alpha Honorary Medical Society

Selected Publications

  1. Unexpected insights for anti-EGFR cancer therapy. Oncotarget. 2015 Aug 7; 6(22):18746-7.
    View on PubMed
  2. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol. 2015 Jun; 17(6):804-15.
    View on PubMed
  3. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014 Sep; 147(3):637-45.
    View on PubMed
  4. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013 Oct 10; 31(29):3664-72.
    View on PubMed
  5. Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress. PLoS One. 2013; 8(9):e73817.
    View on PubMed
  6. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87.
    View on PubMed
  7. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2013 Aug; 2(4):496-506.
    View on PubMed
  8. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600.
    View on PubMed
  9. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013 May 10; 31(14):1775-81.
    View on PubMed
  10. Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc Natl Acad Sci U S A. 2013 Jan 2; 110(1):93-8.
    View on PubMed
  11. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas. 2012 Aug; 41(6):840-4.
    View on PubMed
  12. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs. 2012 Dec; 30(6):2219-25.
    View on PubMed
  13. Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint. Am Soc Clin Oncol Educ Book. 2012; 193-200.
    View on PubMed
  14. Complete and safe resection of challenging retroperitoneal tumors: anticipation of multi-organ and major vascular resection and use of adjunct procedures. World J Surg Oncol. 2011; 9:143.
    View on PubMed
  15. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol. 2011 Aug 10; 29(23):3153-62.
    View on PubMed
  16. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol. 2011 Aug 10; 29(23):3146-52.
    View on PubMed
  17. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis. Oncogene. 2010 Dec 16; 29(50):6543-56.
    View on PubMed
  18. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010 Sep; 8(9):972-1017.
    View on PubMed
  19. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site. J Surg Res. 2010 Sep; 163(1):47-51.
    View on PubMed
  20. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010 Mar; 145(3):276-80.
    View on PubMed

Go to UCSF Profiles, powered by CTSI